Future of the transdermal drug delivery market – have we barely touched the surface?

ABSTRACT Introduction: Transdermal drug delivery is the movement of drugs across the skin for absorption into the systemic circulation. Transfer of the drug can occur via passive or active means; passive transdermal products do not disrupt the stratum corneum to facilitate delivery whereas active technologies do. Due to the very specific physicochemical properties necessary for successful passive transdermal drug delivery, this sector of the pharmaceutical industry is relatively small. There are many well-documented benefits of this delivery route however, and as a result there is great interest in increasing the number of therapeutic substances that can be delivered transdermally. Areas Covered: This review discusses the various transdermal products that are currently/have been marketed, and the paths that led to their success, or lack of. Both passive and active transdermal technologies are considered with the advantages and limitations of each highlighted. In addition to marketed products, technologies that are in the investigative stages by various pharmaceutical companies are reviewed. Expert Opinion: Passive transdermal drug delivery has made limited progress in recent years, however with the ongoing intense research into active technologies, there is great potential for growth within the transdermal delivery market. A number of active technologies have already been translated into marketed products, with other platforms including microneedles, rapidly progressing towards commercialisation.

[1]  Richard H Guy,et al.  Transdermal drug delivery: 30+ years of war and still fighting! , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[2]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[3]  Shuai Xu,et al.  Therapeutic transdermal drug innovation from 2000 to 2014: current status and outlook. , 2015, Drug discovery today.

[4]  A. Maclennan.  Evidence-based review of therapies at the menopause. , 2009, International journal of evidence-based healthcare.

[5]  Ajay K Banga,et al.  Modulated iontophoretic delivery of small and large molecules through microchannels. , 2012, International journal of pharmaceutics.

[6]  Ryan F. Donnelly,et al.  Design, Optimization and Characterisation of Polymeric Microneedle Arrays Prepared by a Novel Laser-Based Micromoulding Technique , 2010, Pharmaceutical Research.

[7]  Hyunjin Park,et al.  Sonophoresis in transdermal drug deliverys. , 2014, Ultrasonics.

[8]  Mark R Prausnitz,et al.  Microneedle patches: usability and acceptability for self-vaccination against influenza. , 2014, Vaccine.

[9]  Ryan F. Donnelly,et al.  Hydrogel-Forming Microneedle Arrays Can Be Effectively Inserted in Skin by Self-Application: A Pilot Study Centred on Pharmacist Intervention and a Patient Information Leaflet , 2014, Pharmaceutical Research.

[10]  Maelíosa T. C. McCrudden,et al.  Microneedle applications in improving skin appearance , 2015, Experimental dermatology.

[11]  Maelíosa T. C. McCrudden,et al.  The role of microneedles for drug and vaccine delivery , 2014, Expert opinion on drug delivery.

[12]  Jung-Hwan Park,et al.  Microsecond thermal ablation of skin for transdermal drug delivery. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[13]  Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study , 2007, Circulation.

[14]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[15]  Ailsa E Gebbie,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. Writing Group for the Women's Health Initiative Investigators. JAMA 2002; 288(3): 321-333 , 2002, Journal of Family Planning and Reproductive Health Care.

[16]  Thakur Raghu Raj Singh,et al.  Hydrogel-Forming Microneedle Arrays for Enhanced Transdermal Drug Delivery , 2012, Advanced functional materials.

[17]  Samir Mitragotri,et al.  Micro-scale devices for transdermal drug delivery. , 2008, International journal of pharmaceutics.

[18]  K. Duffy,et al.  Facial allergic granulomatous reaction and systemic hypersensitivity associated with microneedle therapy for skin rejuvenation. , 2014, JAMA dermatology.

[19]  Maelíosa T. C. McCrudden,et al.  Microneedles for intradermal and transdermal drug delivery. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[20]  P. Uzor,et al.  Transdermal Drug Delivery , 2012 .

[21]  R. Donnelly,et al.  Patient safety and beyond: what should we expect from microneedle arrays in the transdermal delivery arena? , 2014, Therapeutic delivery.